Stay updated with breaking news from Affimed. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Affimed (NASDAQ:AFMD – Get Free Report)‘s stock had its “overweight” rating restated by equities researchers at Cantor Fitzgerald in a research note issued on Thursday, Benzinga reports. They currently have a $7.00 price target on the biopharmaceutical company’s stock. AFMD has been the subject of several other reports. HC Wainwright reaffirmed a “buy” rating and […]
Affimed (NASDAQ:AFMD – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year target price among analysts […]
Affimed (NASDAQ:AFMD – Free Report) had its target price trimmed by Truist Financial from $8.00 to $6.00 in a report released on Friday morning, Marketbeat reports. They currently have a buy rating on the biopharmaceutical company’s stock. AFMD has been the topic of a number of other research reports. Berenberg Bank restated a buy rating […]
03.08.2023 - HEIDELBERG, Germany, Aug. 03, 2023 (GLOBE NEWSWIRE) - Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release second quarter ...
Affimed (NASDAQ:AFMD – Free Report) – Research analysts at Cantor Fitzgerald issued their FY2024 EPS estimates for Affimed in a note issued to investors on Tuesday, July 11th. Cantor Fitzgerald analyst L. Watsek forecasts that the biopharmaceutical company will post earnings of ($0.37) per share for the year. The consensus estimate for Affimed’s current full-year […]